For a quarter century, Drug Development & Delivery has connected innovators, scientists, and industry leaders while spotlighting the technologies and ideas shaping the future of the industry. We celebrate 25 years of advancing the conversation!
As injectable therapies evolve, so do the challenges of delivering them. Credence MedSystems has launched the Industry Education home on our website where we share practical perspectives on important topics in injectable drug delivery, including larger-volume prefilled syringes, precision intravitreal dosing, dual chamber delivery and other emerging drug delivery challenges.
Over the past few years, several major pharmaceutical companies have carved out or spun off their consumer healthcare (CHC) divisions, creating standalone organizations with the scale and scientific heritage of pharma but the commercial ambitions of fast-moving consumer brands. High-profile examples include Kenvue from Johnson & Johnson, Haleon from GSK and Opella from Sanofi, moves intended to unlock greater focus, agility and capital efficiency in businesses that operate under different market dynamics from prescription pharmaceuticals.
In this case study, OSDPredict™ narrowed formulation options early, focusing development on the most viable strategies which reduced experimental burden and conserved valuable materials.
Dr. Shaukat Ali and Dr. Jim Huang shed light on the challenges and opportunities to improve solubility and enhance oral bioavailability of molecules in nanocrystals or crystalline suspensions.
Laxman Halleppanavar and David Phasey offer a focused perspective on connecting formulation, particle engineering, aseptic manufacturing, device design, and patient use within one scalable development pathway.
Matthew Kihara explains how silicone lends itself to optimization, customization, and therapeutic performance, and that modifying silicone chemistry presents an opportunity to optimize drug release behavior and system performance.
Outsourcing formulation development and manufacturing can help drug developers address complex dosage forms, scale-up risks, regulatory demands, and accelerated timelines by connecting projects with CDMO partners that offer specialized expertise, integrated workflows, and scalable manufacturing support.
Upperton is a UK-based CDMO providing integrated contract development and manufacturing services. Specialising in oral, nasal, pulmonary and sterile dosage forms, Upperton offers a comprehensive range of services designed to support the progression of a molecule from early feasibility through to formulation development, clinical trial manufacture and commercial manufacture.
With over 25 years of experience, Upperton excels in rapid product introductions.
Our project delivery is unparalleled and designed specifically to align with the values and innovation of small to mid-sized pharma companies.
Integrated drug development programs so molecules can become cures, fast
With trusted scientific insight brought to every program, Quotient Sciences is a drug development & manufacturing accelerator helping clients bring molecules to cures, fast.
With drug product development, manufacturing, and clinical testing facilities located in both the US and the UK, Quotient Sciences has worked with customers as a trusted CRDMO partner for over 35 years. Our approach to program design and delivery saves time in getting new therapies to market, without compromising quality and control of the product, data, and processes along the way.
Poor aqueous solubility is a key barrier for a growing share of new drug candidates, limiting their bioavailability and development potential. Evonik’s AEROPERL® 300 Pharma excipient helps formulators improve the solubility and bioavailability of poorly water-soluble APIs. Join presenter Carolina Mathias, Senior Applied Technical Manager at Evonik Smart Effects, on Thursday, November 26 at 9:00 a.m. CET for first-hand formulation guidance.
DRUG DEVELOPMENT DIRECT RESOURCES
Upcoming eNewsletter Features:
November 4 – Drug Delivery
November 11 – Parenteral Contract Manufacturing
November 18 – Controlled Release
November 25 – Bioavailability